{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:16:30Z","timestamp":1772054190209,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"unspecified","delay-in-days":105,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EPSRC Doctoral Training Partnership","award":["EP\/W524311\/1"],"award-info":[{"award-number":["EP\/W524311\/1"]}]},{"name":"the Finnish MS Foundation","award":["decision number: 337530"],"award-info":[{"award-number":["decision number: 337530"]}]},{"name":"the Research Council of Finland\u2019s Flagship InFLAMES","award":["decision number: 357910 and 358823"],"award-info":[{"award-number":["decision number: 357910 and 358823"]}]},{"DOI":"10.13039\/501100002341","name":"the Academy of Finland","doi-asserted-by":"crossref","award":["decision number: 330902"],"award-info":[{"award-number":["decision number: 330902"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Predicting disease progression in multiple sclerosis (MS) remains challenging. PET imaging with 18\u2009kDa translocator protein (TSPO) radioligands can detect microglial and astrocyte activation beyond MRI-visible lesions, which has been shown to be highly predictive of disease progression. We previously demonstrated that nuclear magnetic resonance (NMR)-based metabolomics could accurately distinguish between relapsing-remitting (RRMS) and secondary progressive MS (SPMS). This study investigates whether combining TSPO imaging with metabolomics enhances predictive accuracy in a similar setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Blood samples were collected from 87\u2009MS patients undergoing PET imaging with the TSPO-binding radioligand <jats:sup>11<\/jats:sup>C-PK11195 in Finland. Patient disability was assessed using the expanded disability status scale (EDSS) at baseline and 1 year later. Serum metabolomics was performed to identify biomarkers associated with TSPO binding and disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Greater TSPO availability in the normal-appearing white matter and perilesional regions correlated with higher EDSS. Serum metabolites glutamate (p=0.02), glutamine (p=0.006), and glucose (p=0.008), detected by NMR, effectively distinguished future progressors. These three metabolites alone predicted progression with the same accuracy as TSPO-PET imaging (AUC 0.78; p=0.0001), validated in an independent cohort. Combining serum metabolite data with PET imaging significantly improved predictive power, achieving an AUC of 0.98 (p&lt;0.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Measuring three specific serum metabolites is as effective as TSPO imaging in predicting MS progression. However, integrating TSPO imaging with serum metabolite analysis substantially enhances predictive accuracy. Given the simplicity and affordability of NMR analysis, this approach could lead to more personalised, accessible treatment strategies and serve as a valuable tool for clinical trial stratification.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001026","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:15:16Z","timestamp":1744816516000},"page":"e001026","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02433028","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Daniel E","family":"Radford-Smith","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abi G","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Oxford, Oxford, UK"},{"name":"Department of Chemistry, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-0182","authenticated-orcid":false,"given":"Tereza","family":"Kacerova","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjo","family":"Nylund","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, Turku University Hospital and \u00c5bo Akademi University, Turku, Finland"},{"name":"Clinical Neurosciences University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Sucksdorff","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, Turku University Hospital and \u00c5bo Akademi University, Turku, Finland"},{"name":"Clinical Neurosciences University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Matilainen","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, Turku University Hospital and \u00c5bo Akademi University, Turku, Finland"},{"name":"Clinical Neurosciences University of Turku, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Oechtering","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Maleska Maceski","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Leppert","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Neurology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Probert","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C","family":"Anthony","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Airas","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku, Turku University Hospital and \u00c5bo Akademi University, Turku, Finland"},{"name":"Clinical Neurosciences University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2025072811203979000_7.1.e001026.1","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab301","article-title":"Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET","volume":"4","author":"Nylund","year":"2022","journal-title":"Brain Commun"},{"key":"2025072811203979000_7.1.e001026.2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131698"},{"key":"2025072811203979000_7.1.e001026.3","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awaa275","article-title":"Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis","volume":"143","author":"Sucksdorff","year":"2020","journal-title":"Brain (Bacau)"},{"key":"2025072811203979000_7.1.e001026.4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000975","article-title":"Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis","volume":"8","author":"Roodselaar","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072811203979000_7.1.e001026.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2008.01006.x"},{"key":"2025072811203979000_7.1.e001026.6","doi-asserted-by":"publisher","DOI":"10.1002\/glia.24052"},{"key":"2025072811203979000_7.1.e001026.7","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab240","article-title":"Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach","volume":"3","author":"Yeo","year":"2021","journal-title":"Brain Commun"},{"key":"2025072811203979000_7.1.e001026.8","doi-asserted-by":"crossref","first-page":"12381","DOI":"10.1038\/s41598-020-69119-3","article-title":"A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application","volume":"10","author":"Yeo","year":"2020","journal-title":"Sci Rep"},{"key":"2025072811203979000_7.1.e001026.9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025072811203979000_7.1.e001026.10","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.59"},{"key":"2025072811203979000_7.1.e001026.11","first-page":"158","article-title":"Reference and target region modeling of [11C]-(R)-PK11195 brain studies","volume":"48","author":"Turkheimer","year":"2007","journal-title":"J Nucl Med"},{"key":"2025072811203979000_7.1.e001026.12","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1039\/C9AN01005J","article-title":"Reliable, high-quality suppression of NMR signals arising from water and macromolecules: application to bio-fluid analysis","volume":"144","author":"Aguilar","year":"2019","journal-title":"Analyst"},{"key":"2025072811203979000_7.1.e001026.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2003.10.033"},{"key":"2025072811203979000_7.1.e001026.14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1062"},{"key":"2025072811203979000_7.1.e001026.15","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2025072811203979000_7.1.e001026.16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S0317167100041664","article-title":"The increased susceptibility of women to multiple sclerosis","volume":"19","author":"Duquette","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"2025072811203979000_7.1.e001026.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00537-1"},{"key":"2025072811203979000_7.1.e001026.18","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1212\/WNL.0000000000000905","article-title":"A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis","volume":"83","author":"Dickens","year":"2014","journal-title":"Neurology (ECronicon)"},{"key":"2025072811203979000_7.1.e001026.19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40478-017-0495-8","article-title":"Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease","volume":"5","author":"Jurynczyk","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"2025072811203979000_7.1.e001026.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181758","article-title":"Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"2025072811203979000_7.1.e001026.21","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/130.4.1016S"},{"key":"2025072811203979000_7.1.e001026.22","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-016-2030-x"},{"key":"2025072811203979000_7.1.e001026.23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2013.00059","article-title":"The Glutamate-Glutamine (GABA) Cycle: Importance of Late Postnatal Development and Potential Reciprocal Interactions between Biosynthesis and Degradation","volume":"4","author":"Hertz","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025072811203979000_7.1.e001026.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04487.x"},{"key":"2025072811203979000_7.1.e001026.25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00702-016-1661-z","article-title":"Glutamate, T cells and multiple sclerosis","volume":"124","author":"Levite","year":"2017","journal-title":"J Neural Transm (Vienna)"},{"key":"2025072811203979000_7.1.e001026.26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12974-017-0969-4","article-title":"The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis","volume":"14","author":"Mardiguian","year":"2017","journal-title":"J Neuroinflammation"},{"key":"2025072811203979000_7.1.e001026.27","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0582-3"},{"key":"2025072811203979000_7.1.e001026.28","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/brain\/123.11.2321","article-title":"The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity","volume":"123","author":"Banati","year":"2000","journal-title":"Brain (Bacau)"},{"key":"2025072811203979000_7.1.e001026.29","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24497"},{"key":"2025072811203979000_7.1.e001026.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1653-y"},{"key":"2025072811203979000_7.1.e001026.31","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000443","article-title":"Microglial activation, white matter tract damage, and disability in MS","volume":"5","author":"Rissanen","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072811203979000_7.1.e001026.32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000574","article-title":"Natalizumab treatment reduces microglial activation in the white matter of the MS brain","volume":"6","author":"Sucksdorff","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072811203979000_7.1.e001026.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0908-9"},{"key":"2025072811203979000_7.1.e001026.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178996"},{"key":"2025072811203979000_7.1.e001026.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183020"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:20:49Z","timestamp":1753726849000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjno-2025-001026"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001026","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}